ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP100-22 Service Area Expansion for Minnesota Health Care Programs (MHCP)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 23, 2022
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 1181 - 1190 လၢ 4296 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P25R1-20 Children’s Therapeutic Services and Supports (CTSS) Prior Authorization Requirement
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 01, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP112R1-20 Changes to Electronic Funds Transfer Processes
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 22, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP11-23 Commercial Pharmacy Benefit Exclusion for Cimzia®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 22, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP12-23 Change in Prior Authorization Process for Experimental or Investigative Services
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 22, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
bc-com-pharmprogpolicynotifctn-final-2.8.23-eff-4.1.23.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
bc-mhcp-pharmprogpolicynotifctn-final-eff-3.1.23.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP6-23 Commercial Pharmacy Benefit Exclusion for Briumvi™, Hemgenix®, Rebyota™, and Sunlenca® Injection
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 08, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP7-23 MHCP Pharmacy Benefit Exclusion for Briumvi™, Hemgenix®, Lunsumio™, Rebyota™, Sunlenca® Injection, and Vivimusta
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 08, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP8-23 Commercial Formulary Addition for Growth Hormone Therapeutic Class: Genotropin® (somatropin)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 08, 2023